A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011)
Pediatric Blood & Cancer | May 13, 2015 | Volume: 62 | Issue: 10 | Pages: 1717-1724
10.1002/pbc.25575
| PMID 25976292